PSA and androgen-related gene (AR, CYP17, and CYP19) polymorphisms and the risk of adenocarcinoma at prostate biopsy

DNA and Cell Biology

Volumn 27, Issue 9, 2008, Pages 497-503

  Dos Santos, Rodrigo Mattos ^a   De Jesus, Carlos Márcio Nóbrega ^a   Trindade Filho, José Carlos Souza ^a   Trindade, José Carlos Souza ^a   De Camargo, João Lauro Viana ^a   Rainho, Cláudia Aparecida ^a   Rogatto, Silvia Regina ^a,b  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b A C CAMARGO CANCER CENTER   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; AROMATASE; CYTOCHROME P450 17; PROSTATE SPECIFIC ANTIGEN;

5' UNTRANSLATED REGION; ADULT; AGED; ALLELE; ARTICLE; BLOOD SAMPLING; CANCER RADIOTHERAPY; CANCER RISK; CONTROLLED STUDY; DNA DETERMINATION; DNA POLYMORPHISM; GENE LOCUS; GENOTYPE; HIGH RISK PATIENT; HOMOZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MOSAICISM; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE BIOPSY; PROSTATECTOMY; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANDROGENS; AROMATASE; BIOPSY; CASE-CONTROL STUDIES; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; STEROID 17-ALPHA-HYDROXYLASE;

EID: 50849118440     PISSN: 10445498     EISSN: None     Source Type: Journal    
DOI: 10.1089/dna.2007.0700     Document Type: Article

References (30)

1. Abate-Shen, C., and Shen, M.M. (2000). Molecular genetics of prostate cancer. Genes Dev 14, 2410-2434.
2. Alvarado, C., Beitel, L.K., Sircar, K., Aprikian, A., Trifiro, M., and Gottlieb, B. (2005). Somatic mosaicism and cancer: a micro-genetic examination into the role of the androgen receptor gene in prostate cancer. Cancer Res 65, 8514-8518.
3. Arnold, J.T., Liu, X., Allen, J.D., Le, H., McFann, K.K., and Blackman, M.R. (2007). Androgen receptor or estrogen receptor-beta blockade alters DHEA-, DHT-, and E(2)-induced proliferation and PSA production in human prostate cancer cells. Prostate 67, 1152-1162.
4. Bharaj, B.S., Vassilikis, E.J.K., and Diamandis, E.P. (1999). Rapid and accurate determination of (CAG) repeats in the androgen receptor gene using polymerase chain reaction and automated fragment analysis. Clin Biochem 32, 327-332.
5. Cramer, S.D., Chang, B.L., Rao, A., Hawkins, G.A., Zheng, S.L., Wade, W.N., Cooke, R.T., Thomas, L.N., Bleecker, E.R., Catalona, W.J., Sterling, D.A., Meyers, D.A., Ohar, J., and Xu, J. (2003). Association between genetic polymorphisms in the prostate-specific antigen gene promoter and serum prostate-specific antigen levels. J Natl Cancer Inst 95, 1044-1053.
6. Cussenot, O., Azzouzi, A.R., Nicolaiew, N., Frontmont, G., Mangin, P., Cormier, L., Fournier, G., Valeri, A., Larre, S., Thibault, F., Giordanella, J.P., Pouchard, M., Zheng, Y., Hamdy, F.C., Cox, A., and Cancel-Tassin, G. (2007). Combination of polymorphisms from genes related to estrogen metabolism and risk of prostate cancers: the hidden face of estrogens. J Clin Oncol 25, 3596-3602.
7. Douglas, J.A., Zuhlke, K.A., Beebe-Dimmer, J., Levin, A.M., Gruber, S.B., Wood, D.P., and Cooney, K.A. (2005). Identifying susceptibility genes for prostate cancer - a family-based association study of polymorphisms in CYP17, CYP19, CYP11A1, and LH-β. Cancer Epidemiol Biomarkers Prev 14, 2035-2039.
8. Feigelson, H.S., Ross, R.K., Yu, M.C., Coetzee, G.A., Reichardt, J.K., and Henderson, B.E. (1998). Sex steroid hormones and genetic susceptibility to breast and prostate cancer. Drug Metab Rev 30, 421-434.
9. Forrest, M.S., Edwards, S.M., Houlston, R., Kote-Jarai, Z., Key, T., Allen, N., Knowles, M.A., Turner, F., Ardern-Jones, A., Murkin, A., Williams, S., Oram, R., Bishop, D.T., Eeles, R.A., and CR-UK/BPG UK prostate cancer study collaborators. (2005). Association between hormonal genetic polymorphisms and early-onset prostate cancer. Prostate Cancer Prostatic Dis 8, 95-102.
10. Freedman, M.L., Perace, C.L., Penney, K.L., Hirschhorn, J.N., Kolonel, L.N., Henderson, B.E., and Altshuler, D. (2005). Systematic evaluation of genetic variation at the androgen receptor locus and risk of prostate cancer in a multiethnic cohort study. Am J Hum Genet 76, 82-90.
11. Giovannucci, E. (2002). Is the androgen receptor CAG repeats length significant for prostate cancer? Cancer Epidemiol Biomarkers Prev 11, 985-986.
12. Habuchi, T., Liqing, Z., Suzuki, T., Sasaki, R., Tsuchiya, N., Tachiki, H., Shimoda, N., Satoh, S., Sato, K., Kakehi, Y., Kamoto, T., Ogawa, O., and Kato, T. (2000). Increased risk of prostate cancer and benign prostate hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect. Cancer Res 60, 5710-5713.
13. Haiman, C.A., Stampfer, M.J., Giovannucci, E., Ma, J., Decalo, N.E., Kantoff, P.W., and Hunter, D.J. (2001). The relationship between a polymorphism in CYP17 with plasma hormone levels and prostate cancer. Cancer Epidemiol Biomarkers Prev 10, 743-748.
14. n-expanded neuropathies. Hum Mol Genet 4, 523-527.
15. Loktionov, A. (2004). Common gene polymorphisms, cancer progression and prognosis. Cancer Lett 208, 1-33.
16. Low, Y.L., Taylor, J.I., Grace, P.B., Dowsett, M., Folkerd, E., Doody, D., Dunning, A.M., Scollen, S., Mulligan, A.A., Luben, R.N., Khaw, R.T., Day, N.E., Wareham, N.J., and Bingham, S.A. (2005). Polymorphisms in the CYP19 gene may affect the positive correlations between serum and urine phytoestrogen metabolites and plasma androgen concentrations in men. J Nutr 135, 2680-2686.
17. Mononen, N., Seppälä, E.J., Duggal, P., Autio, V., Ikonen, T., Ellonen, P., Saharinen, J., Saarela, J., Vihinen, M., Tammela, T.L., Kallioniemi, O., Bailey-Wilson, J.E., and Schleutker, J. (2006). Profiling genetic variation along the androgen biosynthesis and metabolism pathways implicates several single nucleotide polymorphisms and their combinations as prostate cancer risk factors. Cancer Res 66, 743-747.
18. Ntais, C., Polycarpou, A., and Tsatsoulis, A. (2003). Molecular epidemiology of prostate cancer: androgens and polymorphisms in androgen-related genes. Eur J Endocrinol 149, 469-477.
19. Onen, I.H., Ekmekci, A., Eroglu, M., Polat, F., and Biri, H. (2007). The association of 5-alpha-reductase II (SRD5A2) and 17 hydroxylase (CYP17) gene polymorphisms with prostate cancer patients in the Turkish population. DNA Cell Biol 26, 100-107.
20. Platz, E.A., and Giovannucci, E. (2004). The epidemiology of sex steroid hormones and their signaling and metabolic pathways in the etiology of prostate cancer. J Steroid Biochem Mol Biol 92, 237-253.
21. Polymeropoulos, M.H., Xiao, H., Rath, D.S., and Merril, C.R. (1991). Tetranucleotide repeat polymorphism at the human aromatase cytochrome P450 gene (CYP19). Nucleic Acids Res 19, 195.
22. Rao, A., and Cramer, S.D. (1999). Identification of a polymorphism in the ARE1 region of the PSA promoter. Proc Am Assoc Cancer Res 40, 65.
23. Ribeiro, M.L., Santos, A., Carvalho-Salles, A.B., and Hackel, C. (2002). Allelic frequencies of six polymorphic markers for risk of prostate cancer. Braz J Med Biol Res 35, 205-213.
24. Schatzl, G., Marberger, M., Remzi, M., Grösser, P., Unterlechner, J., Haidinger, G., Zidek, T., Preyer, M., Micksche, M., and Gsur, A. (2005). Polymorphism in the ARE-I region of prostate-specific antigen gene associated with low serum testosterone level and high-grade prostate cancer. Urology 65, 1141-1145.
25. Tsuchiya, N., Wang, L., Suzuki, H., Segawa, T., Fukuda, H., Narita, S., Shimbo, M., Kamoto, T., Mitsumori, K., Ichikawa, T., Ogawa, O., Nakamura, A., and Habuchi, T. (2006). Impact of IGF-I and CYP19 gene polymorphisms on the survival of patients with metastatic prostate cancer. J Clin Oncol 24, 1982-1989.
26. Xue, W., Coetzee, G.A., Ross, R.K., Irvine, R., Kolonel, L., Henderson, B.E., and Ingles, S.A. (2001). Genetic determinants of serum prostate-specific antigen levels in healthy men from a multiethnic cohort. Cancer Epidemiol Biomarkers Prev 10, 575-579.
27. Xue, W., Irvine, R.A., Yu, M.C., Ross, R.K., Coetzee, G.A., and Ingles, S.A. (2000). Susceptibility to prostate cancer: interaction between genotypes at the androgen receptor and prostatespecific antigen loci. Cancer Res 60, 839-841.
28. Yang, Q.F., Sakurai, T., Shan L., Yu, Z., Yoshimura, G., Suzuma, T., Umemura, T., Nakamura, M., Nakamura, Y., Mori, I., and Kakudo, K. (2000). Novel polymorphisms of prostate-specific antigen (PSA) gene associated with PSA mRNA expression in breast cancer. Hum Genet 45, 363-366.
29. Yang, Q., Shan, L., Segawa, N., Nakamura, M., Nakamura, Y., Mori, I., Sakurai, T., and Kakudo, K. (2001). Novel polymorphisms in prostate specific antigen gene and its association with prostate cancer. Anticancer Res 21, 197-200.
30. Zeegers, M.P., Kienemey, L.A.L.M., Nieder, A.M., and Ostrer, H. (2004). How strong is the association between CAG and GGN repeat length polymorphisms in the androgen receptor gene and prostate cancer risk? Cancer Epidemiol Biomarkers Prev 13, 1765-1771.